Digest Network Come funziona
Network
/
Società
Ar
Non verificato

Aro Biotherapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

6 comunicati stampa

Guarda tutti i comunicati
24/09/2025
Industria
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Aro Biotherapeutics Completes Enrollment in Phase 1b Trial of Targeted siRNA Therapy, ABX1100, in Late-Onset Pompe Disease (LOPD)
Fonte
Aro Biotherapeutics
Emittente
Business Wire
1.00
0
11/02/2025
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Mercato del lavoro
Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer
Fonte
Aro Biotherapeutics
Emittente
Business Wire
1.00
0
05/02/2025
Igiene alimentare
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Industria
Aro Biotherapeutics Announces U.S. FDA Clearance of IND Application for ABX1100 for Potential Treatment of Late-Onset Pompe Disease (LOPD)
Fonte
Aro Biotherapeutics
Emittente
Business Wire
1.00
0
23/01/2025
Industria
Igiene alimentare
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Aro Biotherapeutics Doses First Patient in Phase 1b Trial of ABX1100 in Late-Onset Pompe Disease (LOPD)
Fonte
Aro Biotherapeutics
Emittente
Business Wire
1.00
0
07/01/2025
Mercato del lavoro
Igiene alimentare
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Aro Biotherapeutics Appoints Glenn Crater, MD, as Chief Medical Officer
Fonte
Aro Biotherapeutics
Emittente
Business Wire
1.00
0
29/10/2024
Industria
Igiene alimentare
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Aro Biotherapeutics Opens Enrollment of Phase 1b Trial of ABX1100 in Patients with Late-Onset Pompe Disease (LOPD)
Fonte
Aro Biotherapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0